26-a-11567-Acc Mavacamten Demonstrates Clinical and Hemodynamic Benefits in Symptomatic Obstructive Hypertrophic Cardiomyopathy With Only Provocable Outflow Gradients: Real-World Experience From Marvel-HCM | Synapse
March 31, 2026Journal of the American College of Cardiology0 citations
26-a-11567-Acc Mavacamten Demonstrates Clinical and Hemodynamic Benefits in Symptomatic Obstructive Hypertrophic Cardiomyopathy With Only Provocable Outflow Gradients: Real-World Experience From Marvel-HCM